Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1467-1474

  Eremo, Anna Göthlin ^a   Wegman, Pia ^a   Stål, Olle ^b   Nordenskjöld, Bo ^b   Fornander, Tommy ^c   Wingren, Sten ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Randomized patients; Tamoxifen; Wwox

Indexed keywords

PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; WWOX PROTEIN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER TISSUE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MICROSCOPY; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SURVIVAL RATE; TISSUE MICROARRAY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; OXIDOREDUCTASES; PROGNOSIS; TAMOXIFEN; TUMOR SUPPRESSOR PROTEINS;

EID: 84874702740     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2261     Document Type: Article

References (46)

1. Ring A and Dowsett M: Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11: 643-658, 2004.
2. Greenspan EM: Tamoxifen in early breast cancer. Lancet 1: 655, 1983.
3. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M and Rasmussen BB: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1: 16-19, 1985.
4. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA and Greene GL: The structural basis of estrogen receptor/coacti¬vator recognition and the antagonism of this interaction by tamoxifen. Cell 95: 927-937, 1998.
5. Stewart HJ and Prescott R: Adjuvant tamoxifen therapy and receptor levels. Lancet 1: 573, 1985.
6. Paige AJ, Taylor KJ, Taylor C, Hillier SG, Farrington S, Scott D, Porteous DJ, Smyth JF, Gabra H and Watson JE: WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 98: 11417-11422, 2001.
7. Aqeilan RI, Trapasso F, Hussain S, Costinean S, Marshall D, Pekarsky Y, Hagan JP, Zanesi N, Kaou M, Stein GS, et al: Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA 104: 3949-3954, 2007.
8. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA and Aldaz CM: WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 60: 2140-2145, 2000.
9. Nunez MI, Ludes-Meyers J, Abba MC, Kil H, Abbey NW, Page RE, Sahin A, Klein-Szanto AJ and Aldaz CM: Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat 89: 99-105, 2005.
10. Pluciennik E, Kusinska R, Potemski P, Kubiak R, Kordek R and Bednarek AK: WWOX-The FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur J Surg Oncol 32: 153-157, 2006.
11. Driouch K, Prydz H, Monese R, Johansen H, Lidereau R and Frengen E: Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene 21: 1832-1840, 2002.
12. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, Hauck WW, McCue P and Huebner K: The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 100: 1605-1614, 2004.
13. Nunez MI, Ludes-Meyers J and Aldaz CM: WWOX protein expression in normal human tissues. J Mol Histol 37: 115-125, 2006.
14. Bednarek AK, Keck-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K, Brenner AJ and Aldaz CM: WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 61: 8068-8073, 2001.
15. Aqeilan RI, Kuroki T, Pekarsky Y, Albagha O, Trapasso F, Baffa R, Huebner K, Edmonds P and Croce CM: Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 10: 3053-3058, 2004.
16. Baykara O, Demirkaya A, Kaynak K, Tanju S, Toker A and Buyru N: WWOX gene may contribute to progression of non-small-cell lung cancer (NSCLC). Tumour Biol 31: 315-320, 2010.
17. Bloomston M, Kneile J, Butterfield M, Dillhoff M, Muscarella P, Ellison EC, Melvin WS, Croce CM, Pichiorri F, Huebner, et al: Coordinate loss of fragile gene expression in pancreatobiliary cancers: correlations among markers and clinical features. Ann Surg Oncol 16: 2331-2338, 2009.
18. Fabbri M, Iliopoulos D, Trapasso F, Aqeilan RI, Cimmino A, Zanesi N, Yendamuri S, Han SY, Amadori D, Huebner K, et al: WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci USA 102: 15611 15616, 2005.
19. Finnis M, Dayan S, Hobson L, Chenevix-Trench G, Friend K, Ried K, Venter D, Woollatt E, Baker E and Richards RI: Common chromosomal fragile site FRA16D mutation in cancer cells. Hum Mol Genet 14: 1341-1349, 2005.
20. Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA, Palazzo J, McCue PA, Baffa R and Huebner K: Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 24: 1625 1633, 2005.
21. Iliopoulos D, Fabbri M, Druck T, Qin HR, Han SY and Huebner K: Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res 13: 268-274, 2007.
22. Kuroki T, Yendamuri S, Trapasso F, Matsuyama A, Aqeilan RI, Alder H, Rattan S, Cesari R, Nolli ML, Williams NN, et al: The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 10: 2459-2465, 2004.
23. O'Keefe LV, Liu Y, Perkins A, Dayan S, Saint R and Richards RI: FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila. Oncogene 24: 6590-6596, 2005.
24. Park SW, Ludes-Meyers J, Zimonjic DB, Durkin ME, Popescu NC and Aldaz CM: Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer 91: 753-759, 2004.
25. Qin HR, Iliopoulos D, Semba S, Fabbri M, Druck T, Volinia S, Croce CM, Morrison CD, Klein RD and Huebner K: A role for the WWOX gene in prostate cancer. Cancer Res 66: 6477-6481, 2006.
26. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P and Huebner K: Concordant loss of fragile gene expression early in breast cancer development. Pathol Int 55: 471-478, 2005.
27. Chang NS, Schultz L, Hsu LJ, Lewis J, Su M and Sze CI: 17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo. Oncogene 24: 714-723, 2005.
28. Guler G, Himmetoglu C, Jimenez RE, Geyer SM, Wang WP, Costinean S, Pilarski RT, Morrison C, Suren D, Liu J, et al: Aberrant expression of DNA damage response proteins is asso¬ciated with breast cancer subtype and clinical features. Breast Cancer Res Treat 129: 421-432, 2010.
29. Aqeilan RI, Pekarsky Y, Herrero JJ, Palamarchuk A, Letofsky J, Druck T, Trapasso F, Han SY, Melino G, Huebner K, et al: Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci USA 101: 4401 4406, 2004.
30. Chang NS, Doherty J, Ensign A, Schultz L, Hsu LJ and Hong Q: WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phos-phorylated p53. J Biol Chem 280: 43100-43108, 2005.
31. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M and Huebner K: Wwox and Ap2gamma expression levels predict tamoxifen response. Clin Cancer Res 13: 6115-6121, 2007.
32. Guler G, Huebner K, Himmetoglu C, Jimenez RE, Costinean S, Volinia S, Pilarski RT, Hayran M and Shapiro CL: Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer 115: 899-908, 2009.
33. Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky Y, Sudol M and Croce CM: WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 65: 6764 6772, 2005.
34. Aqeilan RI, Donati V, Gaudio E, Nicoloso MS, Sundvall M, Korhonen A, Lundin J, Isola J, Sudol M, Joensuu H, et al: Association of Wwox with ErbB4 in breast cancer. Cancer Res 67: 9330-9336, 2007.
35. Abdeen SK, Salah Z, Maly B, Smith Y, Tufail R, Abu-Odeh M, Zanesi N, Croce CM, Nawaz Z and Aqeilan RI: Wwox inac-tivation enhances mammary tumorigenesis. Oncogene 30: 3900-3906, 2011.
36. Rutqvist LE, Johansson H and Group SBCS: Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 46: 133-145, 2007.
37. Wang X, Chao L, Ma G, Chen L, Zang Y and Sun J: The prog¬nostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype. J Cancer Res Clin Oncol 137: 271-278, 2011.
38. Fox EM, Andrade J and Shupnik MA: Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 74: 622-627, 2009.
39. Yang Z, Barnes CJ and Kumar R: Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 10: 3621-3628, 2004.
40. Watanabe A, Hippo Y, Taniguchi H, Iwanari H, Yashiro M, Hirakawa K, Kodama T and Aburatani H: An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 63: 8629-8633, 2003.
41. Qin HR, Iliopoulos D, Nakamura T, Costinean S, Volinia S, Druck T, Sun J, Okumura H and Huebner K: Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling. Mol Cancer Res 5: 957-965, 2007.
42. Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA and Parsons SJ: Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 20: 1465-1475, 2001.
43. Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis I, Kawakatsu H, Nicholson R and Hiscox S: Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther 8: 1550-1558, 2009.
44. Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J, Eskelinen M and Kosma VM: Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer 40: 1485-1495, 2004.
45. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Härkönen P, Joensuu H, Isola J and Elenius K: Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 65: 1384-1393, 2005.
46. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R and Jones FE: The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res 68: 6387-6395, 2008.